Shannon McConnaughey, MD
Cardiovascular Disease · Meridian, IDNPI 1689093395
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,667 of the $5,849 with a category attached, or 62.7%. 5 manufacturers reported payments, led by Boston Scientific at 51.3% of the total. Reporting peaked in 2024 at $2,134 and has fallen 54.2% since, to $976 in 2025.
Across 190 payments — averaging $30.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$3K
- Abbott$2K
- Edwards Lifesciences$411
- Abiomed$141
- Bracco Diagnostics Inc.$32
What the payments were for
- Travel & lodging$2,18237%
- Food & beverage$3,66763%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 165 | $3,003 |
| Abbott | 18 | $2,262 |
| Edwards Lifesciences | 5 | $411 |
| Abiomed | 1 | $141 |
| Bracco Diagnostics Inc. | 1 | $32 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MitraClip$492
- MitraClip System$264
- PASCAL$213
- Impella$141
How this compares
$5,849 in reported general payments places this provider in the 75th percentile of 59 cardiovascular disease providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 121 | $151,878 |
| JardianceEmpagliflozin | 29 | $35,637 |
| FarxigaDapagliflozin Propanediol | 16 | $15,062 |
| Metoprolol Succinate | 106 | $1,975 |
| Rosuvastatin Calcium | 118 | $1,289 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 29 | $837 |
| Atorvastatin Calcium | 64 | $635 |
| Flecainide Acetate | 11 | $579 |
| Losartan Potassium | 59 | $519 |
| Ezetimibe | 24 | $469 |
| Metoprolol Tartrate | 64 | $398 |
| Spironolactone | 30 | $259 |
| Amiodarone Hcl | 13 | $243 |
| ClopidogrelClopidogrel Bisulfate | 17 | $173 |
| Lisinopril | 28 | $141 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Meridian
- Brian NolanMeridian$739
- Andrew ChaiMeridian$166
- Spencer MillerMeridian$96
- Kristin LinzmeyerMeridian$0
- David HinchmanBoise$324K
- Jacob DelarosaPocatello$226K
- David LaxsonKetchum$135K
- Ryan LongmorePocatello$60K
- Robyn BrydeBoise$27K
- Ronald FritzCoeur D Alene$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.